Resultados de búsqueda - Richárd Márkus

  • Mostrando 1 - 7 Resultados de 7
Limitar resultados
  1. 1
    A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects

    A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects por Vladimir Hanes, Vincent Chow, Nan Zhang, Richárd Márkus

    Publicado 2017
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  2. 2
    A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab

    A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab por Primal Kaur, Vincent Chow, Nan Zhang, Michael Moxness, Arunan Kaliyaperumal, Richárd Márkus

    Publicado 2016
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  3. 3
    Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community

    Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community por Richárd Márkus, Jennifer Liu, Monica Ramchandani, Diana Landa, Teresa L. Born, Primal Kaur

    Publicado 2017
    Enlace del recurso Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  4. 4
    Estimation of Cachexia among Cancer Patients Based on Four Definitions

    Estimation of Cachexia among Cancer Patients Based on Four Definitions por Kathleen M. Fox, John M. Brooks, Shravanthi R. Gandra, Richárd Márkus, Chiun‐Fang Chiou

    Publicado 2009
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  5. 5
    Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial

    Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial por Gabriela Senti, Bettina M. Prinz Vavricka, Iris Erdmann, Mella I. Diaz, Richárd Márkus, Stephen J. McCormack, John Simard, Brunello Wüthrich, Reto Crameri, Nicole Graf, Pål Johansen, Thomas M. Kündig

    Publicado 2008
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  6. 6
    Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis

    Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis por Ronald L. Gibson, George Retsch‐Bogart, Christopher M. Oermann, Carlos Milla, Joseph M. Pilewski, Cori Daines, Richard C. Ahrens, Kevin León, Morty Cohen, Sharon McNamara, Tracy L. Callahan, Richárd Márkus, Jane L. Burns

    Publicado 2006
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  7. 7
    NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety Perspectives

    NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety Perspectives por Andrew D. Zelenetz, Islah Ahmed, Edward L. Braud, James D. Cross, Nancy Davenport-Ennis, Barry D. Dickinson, Steven E. Goldberg, Scott Gottlieb, Philip E. Johnson, Gary H. Lyman, Richárd Márkus, Ursula A. Matulonis, Denise K. Reinke, Edward C. Li, Jessica K. DeMartino, Jonathan K. Larsen, James M. Hoffman

    Publicado 2011
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:

Herramientas de búsqueda: